HUTCHISON CHINA MED. Stock London S.E.
Stocks
Pharmaceuticals
OTC Markets Traded| Market Cap | 2.46B 2.19B 2.04B 1.86B 3.5B 237B 3.53B 24.69B 9.61B 121B 9.23B 9.03B 389B | P/E 2026 * |
45.5x | P/E 2027 * | 41.4x |
|---|---|---|---|---|---|
| Enterprise Value | 1.89B 1.69B 1.57B 1.43B 2.7B 182B 2.72B 19.02B 7.4B 93.11B 7.11B 6.96B 299B | EV / Sales 2026 * |
3.02x | EV / Sales 2027 * | 2.62x |
| Free-Float |
61.2% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: HUTCHISON CHINA MED.
| 1 day | -2.79% |
| Manager | Title | Age | Since |
|---|---|---|---|
Chig Fung Cheng
CEO | Chief Executive Officer | 59 | 2025-08-24 |
Michael Shi
CTO | Chief Tech/Sci/R&D Officer | 61 | 2021-12-31 |
Karen Atkin
COO | Chief Operating Officer | 60 | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Edith Shih
BRD | Director/Board Member | 74 | 2005-12-31 |
Chig Fung Cheng
BRD | Director/Board Member | 59 | 2010-12-31 |
Wei Guo Su
BRD | Director/Board Member | 68 | 2017-03-26 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.79% | -0.24% | - | - | 2.46B | |
| +0.02% | -3.52% | +36.11% | +111.11% | 1,019B | |
| -1.21% | -6.99% | +34.08% | +60.96% | 610B | |
| +1.12% | -0.20% | +13.62% | +80.24% | 470B | |
| -3.30% | -6.15% | +56.45% | +34.69% | 344B | |
| +0.93% | -1.83% | +21.65% | +41.43% | 336B | |
| +0.12% | -4.05% | +10.70% | +33.53% | 266B | |
| -0.89% | -5.83% | -7.00% | +7.91% | 241B | |
| -0.01% | -3.62% | +35.28% | +52.02% | 218B | |
| -0.08% | -4.98% | +28.34% | +93.61% | 179B | |
| Average | -0.09% | -3.63% | +25.47% | +57.28% | 409.2B | |
| Weighted average by Cap. | +0.45% | -3.51% | +28.40% | +68.66% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 627M 559M 521M 474M 893M 60.35B 899M 6.29B 2.45B 30.8B 2.35B 2.3B 99B | 699M 623M 581M 529M 995M 67.3B 1B 7.02B 2.73B 34.35B 2.62B 2.57B 110B |
| Net income | 61.47M 54.84M 51.09M 46.49M 87.55M 5.92B 88.2M 617M 240M 3.02B 231M 226M 9.71B | 70.75M 63.12M 58.8M 53.51M 101M 6.81B 102M 711M 276M 3.48B 266M 260M 11.18B |
| Net Debt | -565M -504M -469M -427M -804M -54.39B -810M -5.67B -2.21B -27.76B -2.12B -2.07B -89.23B | -629M -561M -523M -476M -896M -60.62B -903M -6.32B -2.46B -30.94B -2.36B -2.31B -99.44B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
